- Home
- BSM vs KNSA Comparison
BSM vs KNSA Comparison
Compare BSM & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- KNSA
- Stock Information
- Founded
- BSM 1876
- KNSA 2015
- Country
- BSM United States
- KNSA United Kingdom
- Employees
- BSM N/A
- KNSA N/A
- Industry
- BSM Oil & Gas Production
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- BSM Energy
- KNSA Health Care
- Exchange
- BSM Nasdaq
- KNSA Nasdaq
- Market Cap
- BSM 2.5B
- KNSA 2.6B
- IPO Year
- BSM 2015
- KNSA 2018
- Fundamental
- Price
- BSM $13.31
- KNSA $38.37
- Analyst Decision
- BSM Hold
- KNSA Strong Buy
- Analyst Count
- BSM 1
- KNSA 7
- Target Price
- BSM $13.00
- KNSA $49.71
- AVG Volume (30 Days)
- BSM 462.8K
- KNSA 546.2K
- Earning Date
- BSM 11-03-2025
- KNSA 10-28-2025
- Dividend Yield
- BSM 9.02%
- KNSA N/A
- EPS Growth
- BSM N/A
- KNSA N/A
- EPS
- BSM 1.16
- KNSA 0.47
- Revenue
- BSM $412,814,000.00
- KNSA $597,973,000.00
- Revenue This Year
- BSM $1.60
- KNSA $62.63
- Revenue Next Year
- BSM $10.48
- KNSA $29.93
- P/E Ratio
- BSM $11.50
- KNSA $82.19
- Revenue Growth
- BSM N/A
- KNSA 55.68
- 52 Week Low
- BSM $11.78
- KNSA $17.82
- 52 Week High
- BSM $15.66
- KNSA $42.05
- Technical
- Relative Strength Index (RSI)
- BSM 57.76
- KNSA 52.71
- Support Level
- BSM $12.93
- KNSA $36.56
- Resistance Level
- BSM $13.44
- KNSA $39.66
- Average True Range (ATR)
- BSM 0.21
- KNSA 1.58
- MACD
- BSM 0.03
- KNSA -0.13
- Stochastic Oscillator
- BSM 82.39
- KNSA 50.78
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.